Hammer Gregory B, Philip Bridget M, Schroeder Alan R, Rosen Frederick S, Koltai Peter J
Department of Anesthesia, Stanford University School of Medicine, Lucile Packard Children's Hospital, Stanford, CA 94305-5640, USA.
Paediatr Anaesth. 2005 Jul;15(7):616-20. doi: 10.1111/j.1460-9592.2005.01656.x.
Dexmedetomidine is a centrally acting alpha-2 adrenergic agonist that is currently approved by the US Food and Drug Administration for short-term use (< or = 24 h) to provide sedation in adults in the ICU. This drug has been shown to be efficacious in adult medical and surgical patients in providing sedation, anxiolysis, and analgesia. Dexmedetomidine has been associated with rapid onset and offset, hemodynamic stability, and a natural, sleep-like state in mechanically ventilated adults. To date, there are few publications of the use of this drug in children, and prolonged infusion has not been described. We report our use of dexmedetomidine in a child during a 4-day period of mechanical ventilation following tracheal reconstruction for subglottic stenosis.
右美托咪定是一种中枢作用的α-2肾上腺素能激动剂,目前已获美国食品药品监督管理局批准用于短期使用(≤24小时),为重症监护病房的成人提供镇静作用。该药已被证明对成年内科和外科患者在提供镇静、抗焦虑和镇痛方面有效。右美托咪定具有起效快、作用消失快、血流动力学稳定以及能使机械通气的成年人处于自然、类似睡眠状态的特点。迄今为止,关于该药在儿童中的应用的出版物很少,且尚未有关于长期输注的描述。我们报告了在一名因声门下狭窄行气管重建术后机械通气4天期间使用右美托咪定的情况。